<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02819856</url>
  </required_header>
  <id_info>
    <org_study_id>SPI-3005-501</org_study_id>
    <nct_id>NCT02819856</nct_id>
  </id_info>
  <brief_title>SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SPI-1005 in Cystic Fibrosis (CF) Patients With Acute Pulmonary Exacerbation (APE) Receiving IV Tobramycin at Risk for Ototoxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sound Pharmaceuticals, Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cystic Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sound Pharmaceuticals, Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the safety and efficacy of SPI-1005
      treatment in CF patients with active pulmonary exacerbation that are receiving an IV course
      of tobramycin, determined by comparing hearing assessments, spirometry, Pharmacokinetic (PK),
      Physical Exam, Adverse Events (AEs) and Labs baseline to post-treatment.

      The secondary objectives of this study are to determine Pharmacogenomics and Pharmacodynamics
      of SPI-1005.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, double-blind, placebo-controlled study to evaluate the safety, and efficacy of
      SPI-1005 in Cystic Fibrosis patients with Acute Pulmonary Exacerbation receiving intravenous
      tobramycin at risk for ototoxicity. All patients will undergo baseline testing and have their
      severity of lung function, sensorineural hearing loss, tinnitus and vertigo determined before
      the start of SPI-1005 treatment. SPI-1005 treatment will start within first two days of IV
      tobramycin treatment and be administered concomitantly. At the end of the 21-day course of
      SPI-1005 and 28 days following the cessation of SPI-1005, patients will have their hearing
      loss, tinnitus and vertigo reassessed. Assessments may also include additional audiometric
      and pulmonary testing, and additional follow-up testing.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 21, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with sensorineural hearing loss as a measure of safety and efficacy of SPI-1005</measure>
    <time_frame>7 weeks</time_frame>
    <description>Determination of sensorineural hearing loss using pure-tone audiometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Distortion Product Otoacoustic Emissions</measure>
    <time_frame>7 weeks</time_frame>
    <description>Changes in hearing thresholds using pure-tone audiometry with extended high frequency testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Speech discrimination</measure>
    <time_frame>7 weeks</time_frame>
    <description>Change in Words in noise test (WINT) score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tinnitus severity</measure>
    <time_frame>7 weeks</time_frame>
    <description>Changes in Tinnitus Functional Index (TFI) score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vertigo severity</measure>
    <time_frame>7 weeks</time_frame>
    <description>vertigo symptom scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in lung function</measure>
    <time_frame>7 weeks</time_frame>
    <description>Evaluation of lung function using FEV1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough Level of SPI-1005 at 200, 400, and 600 mg Ebselen po bid x 21d</measure>
    <time_frame>7 weeks</time_frame>
    <description>Plasma ebselen and major metabolite quantified in plasma by LC-MS/MS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenomics</measure>
    <time_frame>5 weeks</time_frame>
    <description>Pharmacogenomics analysis will explore SPI‑1005 as an inducer of gene expression for Nrf2, glutathione peroxidase-1, hemeoxygenase-1, and thioredoxin class of redox proteins.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of Nrf2</measure>
    <time_frame>5 weeks</time_frame>
    <description>Explore SPI‑1005 on the level of Nrf2 by PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of Glutathione, cysteine and cystine</measure>
    <time_frame>5 weeks</time_frame>
    <description>Explore SPI‑1005 on the level of Glutathione, cysteine and cystine measured in µM.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Ototoxicity</condition>
  <arm_group>
    <arm_group_label>SPI-1000 Capsule 0mg Ebselen Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0mg Ebselen SPI-1000 bid po x 21d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPI-1005 Ebselen 200mg Capsule x1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg SPI-1005 bid po x 21d Low Dose Arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPI-1005 Ebselen 200mg Capsule x2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400mg SPI-1005 bid po x 21d Mid Dose Arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPI-1005 Ebselen 200mg Capsule x3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600mg SPI-1005 bid po x 21d High Dose Arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0 mg SPI-1005 bid po x 21d</description>
    <arm_group_label>SPI-1000 Capsule 0mg Ebselen Placebo</arm_group_label>
    <other_name>SPI-1000</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPI-1005 Ebselen 200mg Capsule x1</intervention_name>
    <description>200 mg SPI-1005 bid po x21d</description>
    <arm_group_label>SPI-1005 Ebselen 200mg Capsule x1</arm_group_label>
    <other_name>SPI-1005 Low Dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPI-1005 Ebselen 200mg Capsule x2</intervention_name>
    <description>400 mg SPI-1005 bid po x 21d</description>
    <arm_group_label>SPI-1005 Ebselen 200mg Capsule x2</arm_group_label>
    <other_name>SPI-1005 Mid Dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPI-1005 Ebselen 200mg Capsule x3</intervention_name>
    <description>600 mg SPI-1005 bid po x 21d</description>
    <arm_group_label>SPI-1005 Ebselen 200mg Capsule x3</arm_group_label>
    <other_name>SPI-1005 High Dose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cystic fibrosis patients about to receive IV tobramycin for acute pulmonary
             exacerbation.

          -  Voluntarily consent to participate in the study.

          -  Females of childbearing potential should be using and committed to continue using one
             of the following acceptable birth control methods:

          -  Sexual abstinence (inactivity) for 14 days prior to screening through study
             completion; or IUD in place for at least 3 months prior to study through study
             completion; or Barrier method (condom or diaphragm) with spermicide for at least 14
             days prior to screening through study completion; or Stable hormonal contraceptive for
             at least 3 months prior to study through study completion.

          -  Ability to perform all behavioral tests as indicated.

        Exclusion Criteria:

          -  Current use or within 60 days prior to study enrollment the following IV ototoxic
             medications: aminoglycoside antibiotics (gentamicin, tobramycin, amikacin,
             streptomycin); platinum-containing chemotherapies (cisplatin, carboplatin,
             oxaliplatin); or loop diuretic (furosemide).

          -  History of idiopathic sensorineural hearing loss, otosclerosis, or vestibular
             schwannoma.

          -  History of middle ear or inner ear surgery.

          -  Current conductive hearing loss or middle ear effusion.

          -  Significant cardiovascular, hepatic, renal, hematologic, endocrine, immunologic, or
             psychiatric disease.

          -  History of hypersensitivity or idiosyncratic reaction to compounds related to ebselen.

          -  Participation in another investigational drug or device study within 30 days prior to
             study enrollment.

          -  Female patients who are pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Kil, MD</last_name>
    <role>Study Chair</role>
    <affiliation>SOUND PHARMACEUTICALS, INC.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Takumida M, Popa R, Anniko M. Free radicals in the guinea pig inner ear following gentamicin exposure. ORL J Otorhinolaryngol Relat Spec. 1999 Mar-Apr;61(2):63-70.</citation>
    <PMID>10095194</PMID>
  </reference>
  <reference>
    <citation>Kil J, Pierce C, Tran H, Gu R, Lynch ED. Ebselen treatment reduces noise induced hearing loss via the mimicry and induction of glutathione peroxidase. Hear Res. 2007 Apr;226(1-2):44-51. Epub 2006 Oct 6.</citation>
    <PMID>17030476</PMID>
  </reference>
  <reference>
    <citation>Flume PA, Mogayzel PJ Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC; Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009 Nov 1;180(9):802-8. doi: 10.1164/rccm.200812-1845PP. Epub 2009 Sep 3. Review.</citation>
    <PMID>19729669</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>June 16, 2016</study_first_submitted>
  <study_first_submitted_qc>June 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>March 14, 2019</last_update_submitted>
  <last_update_submitted_qc>March 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ebselen</keyword>
  <keyword>Tinnitus</keyword>
  <keyword>Hearing Loss</keyword>
  <keyword>Vertigo</keyword>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Pulmonary Exacerbation</keyword>
  <keyword>Tobramycin</keyword>
  <keyword>Safety</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Aminoglycoside</keyword>
  <keyword>SPI-1005</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Pharmacogenomics</keyword>
  <keyword>Ototoxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ebselen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

